Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06680375 · ClinicalTrials.gov registry record · Phase 1

A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

A Phase 1 study of COVID-19, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 1
Development phase
106
Enrollment target
9
Study locations

NCT06680375 is a Phase 1 study of COVID-19 that has completed, run by GlaxoSmithKline. The registered enrollment target is 106 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06680375, a Phase 1 study of COVID-19, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 1
Development phase
106 participants
Enrollment target
9
Study locations

Study Summary

This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.

Conditions Studied

COVID-19

Interventions

  • COMBINATION_PRODUCT Flu Seasonal /SARS-CoV-2 mRNA Dose 1
  • COMBINATION_PRODUCT Flu Seasonal /SARS-CoV-2 mRNA Dose 2
  • COMBINATION_PRODUCT Flu Seasonal mRNA
  • COMBINATION_PRODUCT SARS-CoV-2 mRNA Dose 1
  • COMBINATION_PRODUCT SARS-CoV-2 mRNA Dose 2

Study Locations (9)

Florida

  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Miami

Alabama

  • GSK Investigational Site - Anniston

California

  • GSK Investigational Site - Rolling Hills Estates

Kansas

  • GSK Investigational Site - Lenexa

Missouri

  • GSK Investigational Site - St Louis

Nebraska

  • GSK Investigational Site - Omaha

New York

  • GSK Investigational Site - Rochester

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2024-11-11
Est. Completion 2025-06-09
Phase Phase 1

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06680375

The ClinicalTrials.gov registry entry for NCT06680375 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 5 interventions - of which Flu Seasonal /SARS-CoV-2 mRNA Dose 1 is the first listed.

NCT06680375 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06680375 about?

NCT06680375 is a clinical study titled "A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults". This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts...

What is the current status of trial NCT06680375?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2024-11-11. Estimated completion is 2025-06-09.

What conditions does trial NCT06680375 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT06680375?

The interventions under investigation include: Flu Seasonal /SARS-CoV-2 mRNA Dose 1 (COMBINATION_PRODUCT), Flu Seasonal /SARS-CoV-2 mRNA Dose 2 (COMBINATION_PRODUCT), Flu Seasonal mRNA (COMBINATION_PRODUCT), SARS-CoV-2 mRNA Dose 1 (COMBINATION_PRODUCT), SARS-CoV-2 mRNA Dose 2 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06680375?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06680375 being conducted?

This trial has 9 study locations across Alabama, California, Florida, Kansas, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.